# The Hypoglycaemic Effects of the New Zealand Pine Bark Extract on Sucrose Uptake and Glycaemic Responses in Healthy Adults—A Single-Blind, Randomised, Placebo-Controlled, Crossover Trial

**Authors:** Wen Xin Janice Lim, Rachel A. Page, Cheryl S. Gammon, Paul J. Moughan

PMC · DOI: 10.3390/nu17142277 · Nutrients · 2025-07-09

## TL;DR

A New Zealand pine bark extract may help lower blood sugar spikes after eating sucrose, according to a study on healthy adults.

## Contribution

This study is the first to demonstrate the hypoglycaemic effects of New Zealand pine bark extract in humans.

## Key findings

- The 400 mg dose of pine bark extract significantly reduced the area under the glucose curve by 14.4%.
- The 50 mg dose significantly reduced the peak glucose value by 5.5%.
- No significant changes in postprandial insulin levels were observed with the extract.

## Abstract

Background: The New Zealand pine bark has been demonstrated in vitro to inhibit digestive enzymes involved in carbohydrate digestion (alpha-amylase, alpha-glucosidase, and dipeptidyl-peptidase 4 (DPP-4)). Objective: This study aims to investigate the inhibitory effects of the New Zealand pine bark on sucrose uptake and glycaemic responses in humans. Methods: A single-blind, randomised, placebo-controlled, crossover trial was carried out involving healthy adults (n = 40 (M: 12, F: 28), 30.1 ± 1.3 years, BMI 23.4 ± 0.5 kg/m2, HbA1c 32.5 ± 0.6 mmol/mol, FBG 4.7 ± 0.1 mmol/L). A control (75 g of sucrose powder only), and two doses of the pine bark extract (50 and 400 mg) were provided on separate occasions, with 75 g of sucrose mixed in 250 mL of water. Blood samples were collected at −10, 0, 15, 30, 45, 60, 90, and 120 min via a finger prick test. A linear mixed model for repeated measures (SPSS v30, IBM) was applied, and data presented as model-adjusted mean ± SEM. Results: Compared to control (247.5 ± 14.0 mmol/L⋅min), the iAUCglucose was significantly reduced with the 400 mg dose (211.8 ± 13.9 mmol/L⋅min, 14.4% reduction, and p = 0.037), but not with 50 mg dose (220.8 ± 14.2 mmol/L⋅min, 10.8% reduction, and p = 0.184). Compared to control (9.1 ± 0.2 mmol/L), glucose peak value was significantly reduced with the 50 mg dose (8.6 ± 0.2 mmol/L, 5.5% reduction, and p = 0.016) but not with the 400 mg dose (8.7 ± 0.2 mmol/L, 4.4% reduction, and p = 0.093). There were no statistically significant changes in postprandial insulin levels with the pine bark extract compared to control. Conclusions: The New Zealand pine bark extract attenuated sucrose uptake with improved glycaemic responses, and may therefore be useful as a hypoglycaemic adjunct to the diet.

## Linked entities

- **Proteins:** LOC1273653 (alpha-amylase 2), DPP4 (dipeptidyl peptidase 4)
- **Chemicals:** sucrose (PubChem CID 5988)

## Full-text entities

- **Genes:** DPP4 (dipeptidyl peptidase 4) [NCBI Gene 1803] {aka ADABP, ADCP2, CD26, DPPIV, TP103}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, SI (sucrase-isomaltase) [NCBI Gene 6476]
- **Chemicals:** Sucrose (MESH:D013395), carbohydrate (MESH:D002241), water (MESH:D014867), pine bark extract (MESH:C024070), New Zealand Pine Bark Extract (-), glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12298276/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12298276/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12298276/full.md

---
Source: https://tomesphere.com/paper/PMC12298276